No Fanfare For US Approval Of Sanofi's GLP-1 Adlyxin
Executive Summary
Sanofi has secured US approval for its a once-daily mealtime GLP-1 injection Adlyxin (lixisenatide) as an adjunct to diet and exercise for the treatment of adults with type 2 diabetes, but as the sixth GLP-1 product to enter this market the drug is unlikely to gain a strong foothold.
You may also be interested in...
'Challenging Quarter' For Sanofi As Questions Hang Over Diabetes Franchise
"A somewhat challenging quarter," was how Sanofi CEO Olivier Brandicourt described the second three months of 2016, but analysts say there were no surprises in the downward trajectory of Sanofi's fortunes. There was also little news on Sanofi's pursuit of Medivation.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.
In Vivo's 2024 Rising Leaders At A Glance
Top 30 leaders: see the list of industry influencers highlighted in the fifth edition of In Vivo's Rising Leaders series.